Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Status:
Completed
Trial end date:
2017-02-07
Target enrollment:
Participant gender:
Summary
The primary objectives are to determine the progression-free survival (PFS) and to evaluate
safety of the trastuzumab, bevacizumab and docetaxel regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Bhuvaneswari Ramaswamy
Collaborators:
Case Comprehensive Cancer Center Genentech, Inc. University of Pittsburgh